A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF INCA036978 IN PARTICIPANTS WITH MYELOPROLIFERATIVE NEOPLASMS
- Registry ID
- INCA 36978-101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- INCYTE CORPORATION
- Start date
- 2026-08-12
- Last update
- 2026-05-22
Conditions
- MYELOPROLIFERATIVE NEOPLASMS
Related clinical trials
- A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF INCB160058 IN PARTICIPANTS WITH MYELOPROLIFERATIVE NEOPLASMS
- A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF INCA033989 ADMINISTERED AS A MONOTHERAPY OR IN COMBINATION WITH RUXOLITINIB IN PARTICIPANTS WITH MYELOPROLIFERATIVE NEOPLASMS
- PROTOCOL 10538, VENETOCLAX IN COMBINATION WITH ASTX727, AN ALL-ORAL THERAPY FOR CHRONIC MYELOMONOCYTIC LEUKEMIA AND OTHER MDS/MPN WITH EXCESS BLASTS (VICTORY-MDS/MPN): A RANDOMIZED, PHASE 2 TRIAL
- A PHASE II OPEN-LABEL STUDY OF COMBINED RUXOLITINIB AND ENASIDENIB IN PATIENTS WITH ACCELERATED/BLAST-PHASE MYELOPROLIFERATIVE NEOPLASM OR CHRONICPHASE MYELOFIBROSIS WITH AN IDH2 MUTATION
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITANT JAK2 INHIBITOR THERAPY AND WHO REQUIRE RED BLOOD CELL TRANSFUSIONS
- SL-401 IN PATIENTS WITH ADVANCED, HIGH RISK MYELOPROLIFERATIVE NEOPLASMS
View on source registry